摘要
弥漫大B细胞淋巴瘤(DLBCL)发病的分子机制目前尚未完全阐明,表观遗传学在其发生发展中发挥了重要作用.微小RNA (miRNA)是表观遗传学中重要的一部分,参与DLBCL的发生发展.相关研究发现miRNA不仅可作为DLBCL的分子诊断标志物,而且可用于判断其预后和治疗效果.
The molecular mechanism of diffuse large B cell lymphoma(DLBCL)has not been fully elucidated,and epigenetics plays an important role in its development.MicroRNAs(miRNAs)are important parts of epigenetics,which are involved in the occurrence and development of DLBCL.Relevant studies have found that miRNAs can not only be used as molecular diagnostic markers of DLBCL,but also be used to judge the prognosis and treatment effect of DLBCL.
作者
孙烨
盛立霞
欧阳桂芳
Sun Ye;Sheng Lixia;Ouyang Guifang(Department of Clinical Medicine,Medical School of Ningbo University,Ningbo 315211,China;Department of Hematology,Ningbo First Hospital,Ningbo 315000,China)
出处
《国际肿瘤学杂志》
CAS
2019年第9期566-569,共4页
Journal of International Oncology
基金
国家自然科学基金(81401321)
浙江省基础公益研究计划(LGF19H080002)
浙江省医药卫生科技计划(2018PY052)。
